Yes, lithium toxicity can occur at therapeutic serum levels
Signs of lithium toxicity can absolutely appear even when serum lithium concentrations are within the therapeutic range, and clinicians must remain vigilant for clinical manifestations regardless of laboratory values. This is explicitly stated in FDA labeling and supported by multiple clinical guidelines and case reports 1.
Key Evidence from FDA Labeling
The FDA black box warning is unequivocal: "Lithium toxicity is closely related to serum lithium levels, and can occur at doses close to therapeutic levels" 1. This warning emphasizes that therapeutic monitoring alone is insufficient—clinical assessment is paramount.
Clinical Manifestations at Therapeutic Levels
The most common presentations of toxicity at therapeutic levels include:
- Neurological symptoms (most frequent): tremor (61.9% of cases), altered mental status, decreased consciousness, gait disturbance/ataxia, speech disturbances, myoclonus 2
- Gastrointestinal symptoms: nausea, vomiting, diarrhea
- Extrapyramidal symptoms: particularly in elderly patients or those on concurrent neuroleptics 3
- "Electrical shock-like" convulsions: reported even with normal serum levels 4
Populations at Highest Risk
Certain patient groups are particularly vulnerable to toxicity despite therapeutic levels:
- Elderly patients (mean age 61 years in case series): age-related changes in renal function and body composition increase susceptibility 2, 3
- Patients on neuroleptics: increased risk of neurotoxicity and extrapyramidal symptoms 3
- Those with renal dysfunction: approximately two-thirds of toxicity cases show elevated creatinine 2
- Patients on interacting medications: particularly NSAIDs, diuretics, ACE inhibitors 5, 6
- Patients with poor dietary intake or reduced sodium: increases lithium retention 4
Critical Risk Factors to Monitor
Beyond serum levels, assess for:
- Polypharmacy: especially antipsychotics, diuretics, antihypertensives, NSAIDs 2, 6
- Dehydration or intercurrent illness 5
- Electrolyte disturbances: hypokalemia, hypomagnesemia 7
- Prolonged lithium exposure: nearly one-third of toxicity cases occur after >10 years of therapy 2
Monitoring Algorithm
The 2021 American Academy of Sleep Medicine guidelines provide specific monitoring recommendations 8:
- During acute phase: Check serum lithium concentrations twice weekly until stable
- Maintenance phase: Monitor every 3-6 months 9
- With each visit: Assess for neurological symptoms (tremor, gait, mental status, speech)
- Regular laboratory monitoring: Renal function (BUN, creatinine), thyroid function, electrolytes 9
- With medication changes: Immediate reassessment if adding NSAIDs, diuretics, or other interacting drugs 5
Management When Toxicity Suspected
Discontinue lithium immediately if clinical toxicity is suspected, even with therapeutic levels 4, 10. The 2014 KDOQI guidelines recommend temporary discontinuation during serious intercurrent illness in patients with GFR <60 mL/min/1.73 m² 5.
Diagnostic aids include:
- Electroencephalography: can support diagnosis of chronic lithium toxicity even when serum levels are therapeutic 10
- Serial lithium levels: to assess trend and clearance
- Comprehensive metabolic panel: to evaluate renal function and electrolytes
Common Pitfall to Avoid
The most critical error is dismissing clinical symptoms of toxicity based solely on therapeutic serum lithium levels. Multiple fatal cases have been reported with levels in the therapeutic range 11. Clinical presentation must take precedence over laboratory values in decision-making.
The 2014 KDOQI guidelines note that lithium is "nephrotoxic and may cause renal tubular dysfunction with prolonged use even at therapeutic levels" 5, emphasizing that chronic toxicity is a distinct entity from acute overdose.
Special Considerations
- Chronic vs. acute toxicity: Chronic toxicity at therapeutic levels presents differently than acute overdose, with predominantly neurological rather than gastrointestinal symptoms 2
- Renal effects: Progressive renal dysfunction can occur even at therapeutic levels, requiring regular GFR monitoring 5, 1
- Drug interactions: The combination of lithium with eplerenone, diuretics, or ACE inhibitors requires particularly close monitoring 12, 5